{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:30:18Z","timestamp":1787016618207,"version":"build-2736575974"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    One hundred sixty-three women with uncomplicated acute lower urinary tract infections were included in a multicenter randomized study comparing cefpodoxime-proxetil (one 100-mg tablet twice daily) with trimethoprim-sulfamethoxazole (one double-strength tablet [160\/800 mg] twice daily) for 3 days. A total of 30 women in both arms were excluded from the study for various reasons. At 4 to 7 days after the discontinuation of therapy, 62 of 63 (98.4%) cefpodoxime-proxetil recipients and 70 of 70 (100%) trimethoprim-sulfamethoxazole patients were clinically cured and demonstrated bacteriological eradication, respectively. At 28 days after treatment, 48 of 55 (87.3%) and 43 of 50 (86%) cefpodoxime-proxetil recipients as well as 51 of 60 (85%) and 42 of 50 (84%) trimethoprim-sulfamethoxazole recipients were clinically cured and demonstrated bacteriological eradication, respectively. Independently of the prescribed regimen, a significant difference (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.001) in failure rates was observed only for patients with a previous history of three or more episodes of acute cystitis per year. With the exception of one patient in the trimethoprim-sulfamethoxazole arm who discontinued therapy because of gastrointestinal pain, both antimicrobials were well tolerated. In conclusion, cefpodoxime-proxetil treatment for 3 days was as safe and effective as trimethoprim-sulfamethoxazole for 3 days for the treatment of uncomplicated acute cystitis in women.\n                  <\/jats:p>","DOI":"10.1128\/aac.47.3.897-900.2003","type":"journal-article","created":{"date-parts":[[2003,2,25]],"date-time":"2003-02-25T13:22:21Z","timestamp":1046179341000},"page":"897-900","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":57,"title":["Cefpodoxime-Proxetil versus Trimethoprim-Sulfamethoxazole for Short-Term Therapy of Uncomplicated Acute Cystitis in Women"],"prefix":"10.1128","volume":"47","author":[{"given":"Demetra","family":"Kavatha","sequence":"first","affiliation":[{"name":"1st Department of Propedeutic Medicine,\u201cLaiko\u201d General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Giamarellou","sequence":"additional","affiliation":[{"name":"4th Department of Propedeutic Medicine, \u201cSismanoglio\u201d General Hospital, Athens Medical School, Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Alexiou","sequence":"additional","affiliation":[{"name":"1st Department of Propedeutic Medicine,\u201cLaiko\u201d General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickolas","family":"Vlachogiannis","sequence":"additional","affiliation":[{"name":"Primary Health Centre of Lavrion, Attica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Pentea","sequence":"additional","affiliation":[{"name":"1st Department of Propedeutic Medicine,\u201cLaiko\u201d General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gozadinos","sequence":"additional","affiliation":[{"name":"Halkida General Hospital, Evia, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garyphalia","family":"Poulakou","sequence":"additional","affiliation":[{"name":"1st Department of Propedeutic Medicine,\u201cLaiko\u201d General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agissilaos","family":"Hatzipapas","sequence":"additional","affiliation":[{"name":"1st Department of Propedeutic Medicine,\u201cLaiko\u201d General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Koratzanis","sequence":"additional","affiliation":[{"name":"4th Department of Propedeutic Medicine, \u201cSismanoglio\u201d General Hospital, Athens Medical School, Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00003495-199300453-00023","volume":"45","year":"1993","unstructured":"Bailey, R. R. 1993. Management of lower urinary tract infections. Drugs45(Suppl. 3):139-144.","journal-title":"Drugs"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/339491"},{"key":"e_1_3_2_4_2","unstructured":"Committee on Safety of Medicine. 1985. Deaths associated with cotrimoxazole ampicillin and trimethoprim. British Society of Antimicrobial Chemotherapy. Her Majesty's Stationery Office London United Kingdom."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003495-199100423-00009","volume":"42","year":"1991","unstructured":"Cox, C. E., J. F. Gravelin, and J. M. Luengo. 1991. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections. Drugs42(Suppl. 3):41-50.","journal-title":"Drugs"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2165\/00003495-199244050-00011","volume":"44","year":"1992","unstructured":"Frampton, J. E., R. N. Brodgen, H. D. Langtry, and M. M. Buckley. 1992. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs44:889-917.","journal-title":"Drugs"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2736"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.2.223"},{"key":"e_1_3_2_9_2","first-page":"277","volume":"153","year":"1989","unstructured":"Greenberg, R. N., P. M. Reilly, K. L. Luppen, W. J. Weinandt, L. L. Ellington, and M. R. Bollinger. 1989. Randomized study of single-dose, three-day, and seven-day treatment of cystitis in women. J. Infect. Dis.153:277-282.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.7.1479"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/clinids\/24.Supplement_1.S63","volume":"24","year":"1997","unstructured":"Huovinen, P. 1997. Increases in rates of resistance to trimethoprim. Clin. Infect. Dis.24(Suppl. 1):63-65.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_12_2","first-page":"67","volume":"43","year":"1999","unstructured":"Iravani, A., I. Klimberg, C. Briefer, C. Munera, S. F. Kowalski, and R. M. Echols. 1999. A trial comparing low-dose ciprofloxacin and standard 7-day therapy with cotrimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infections. J. Antimicrob. Chemother.43(Suppl. A):67-75.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.29.1.107"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00026-1"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/BF01739310","volume":"21","year":"1993","unstructured":"Naber, K. G., and E. M. W. Koch. 1993. Cefuroxime axetil versus ofloxacin for short-term treatment of acute uncomplicated lower urinary tract infections in women. Infection21:40-45.","journal-title":"Infection"},{"key":"e_1_3_2_16_2","unstructured":"National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing. Eleventh informational supplement. M100-S11. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/clinids\/12.3.458","volume":"12","year":"1990","unstructured":"Norby, S. R. 1990. Short-term treatment of uncomplicated lower urinary tract infections in women. Rev. Infect. Dis.12:458-467.","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/339812"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.1176"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/00365548509070425","volume":"17","year":"1985","unstructured":"Sandberg, T., C. Henning, S. Iwarson, and O. Paulsen. 1985. Cefadroxil once daily for three or seven days versus amoxicillin for seven days in uncomplicated urinary tract infections in women. Scand. J. Infect. Dis.17:83-87.","journal-title":"Scand. J. Infect. Dis."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310283291808"},{"key":"e_1_3_2_22_2","unstructured":"Swinscow T. D. V. (revised by M. J. Campbell). 1998. The \u03c7 2 tests p. 68-85. BMJ Publishing Group London United Kingdom."},{"key":"e_1_3_2_23_2","first-page":"85","volume":"43","year":"1999","unstructured":"Tice, A. D. 1999. Short-course therapy of acute cystitis: a brief review of therapeutic strategies. J. Antimicrob. Chemother.43(Suppl. A):85-93.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/24.suppl_B.1"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF01645370","volume":"19","year":"1991","unstructured":"Wiedemann, B., E. Luhmer, and M. T. Zuhlsdorf. 1991. In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, Enterobacteriaceae, and Pseudomonas aeruginosa, including \u03b2-lactamase producers. Infection19:363-369.","journal-title":"Infection"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.3.897-900.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.3.897-900.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T12:56:06Z","timestamp":1645448166000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.3.897-900.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1128\/AAC.47.3.897-900.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.3.897-900.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3]]},"assertion":[{"value":"2002-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-11-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}